Glendon E. French III Sells 2,326 Shares of Pulmonx Co. (NASDAQ:LUNG) Stock

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 2,326 shares of the business’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $6.53, for a total value of $15,188.78. Following the completion of the transaction, the director now owns 1,069,648 shares of the company’s stock, valued at $6,984,801.44. This represents a 0.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Pulmonx Stock Down 1.1 %

Shares of LUNG stock opened at $6.19 on Wednesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. Pulmonx Co. has a fifty-two week low of $5.46 and a fifty-two week high of $14.84. The firm has a market capitalization of $244.44 million, a PE ratio of -4.21 and a beta of 0.66. The stock’s 50-day simple moving average is $6.45 and its 200-day simple moving average is $6.89.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $20.39 million during the quarter, compared to analyst estimates of $20.39 million. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. During the same period last year, the firm posted ($0.39) EPS. Equities analysts expect that Pulmonx Co. will post -1.53 earnings per share for the current year.

Analyst Ratings Changes

LUNG has been the topic of several recent research reports. Wells Fargo & Company dropped their price target on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. Citigroup reissued a “neutral” rating and issued a $7.50 price objective (down previously from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th. Finally, Stifel Nicolaus cut their price target on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $12.75.

Institutional Investors Weigh In On Pulmonx

Several hedge funds have recently added to or reduced their stakes in the business. 272 Capital LP acquired a new position in shares of Pulmonx in the 3rd quarter valued at about $25,000. nVerses Capital LLC purchased a new position in Pulmonx during the third quarter valued at approximately $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Pulmonx in the second quarter valued at approximately $37,000. SG Americas Securities LLC purchased a new stake in Pulmonx in the 3rd quarter worth approximately $102,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Pulmonx during the 2nd quarter worth approximately $93,000. 91.04% of the stock is owned by hedge funds and other institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.